Oppenheimer Anticipates Positive OPTR Vote From FDA

Oppenheimer has released a report on the upcoming FDA advisory panel meeting for Optimer Pharmaceuticals OPTR. According to the report, "We are previewing the FDA advisory panel meeting on April 5th, when panel members will vote on approval of OPTR's antibiotic Fidaxomicin for treatment of Clostridium difficile bacterial infection (CDI). (1) We anticipate a positive vote based on Fidaxomicin's robust Phase III program and benign safety profile. (2) We believe the FDA panel will focus on improvement in recurrence associated with Fidaxomicin, as well as the unmet medical need in CDI. (3) Release of FDA panel documents on April 1st could serve as a positive catalyst and (4) we believe OPTR shares could approach our $14 PT on a positive advisory panel committee vote." OPTR has an Outperform Rating and a $14.00 Price Target. OPTR closed at $12.31 yesterday.